MHCII Beta Chain Variants Enhance CD4 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MHCII tetramer-based approaches in flow cytometry under-sample CD4+ T cells with low but biologically relevant affinity for peptide:MHCII ligands, as they do not effectively utilize CD4 binding to enhance TCR interactions.
Innovation Solution
Development of variant MHCII beta chains with enhanced CD4 affinity through directed evolution, creating tetramers that stabilize weak interactions with TCRs on CD4+ T cells, thereby improving detection and activation of antigen-specific CD4+ T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional MHCII tetramers are used for flow cytometry detection, then the detection method is simple and widely applicable, but CD4+ T cells with low affinity TCRs are under-sampled and not effectively detected
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the MHCII beta chain to create variant molecules with enhanced CD4 binding affinity. Specific amino acid substitutions in the beta chain enable stronger interactions with CD4 co-receptors, thereby improving the detection sensitivity for low affinity TCRs without fundamentally changing the tetramer structure or detection methodology
Solution Approach 2:
The patent creates composite MHCII molecules by combining modified beta chains with alpha chains to form heterodimers that are then tetramerized. This composite structure integrates the peptide-binding capability of MHCII with enhanced CD4 affinity, resulting in a multi-functional reagent that simultaneously maintains TCR recognition and improves CD4 co-receptor engagement for better detection of low affinity interactions
2Reliability
If MHCII tetramers are used to detect CD4+ T cells, then the method can identify antigen-specific T cells, but the low affinity TCR interactions are not stabilized enough for effective detection
Solution Approach 1:
The patent modifies the binding affinity parameter by introducing amino acid substitutions in the MHCII beta chain that specifically enhance CD4 co-receptor binding. These parameter changes increase the strength of the MHCII-CD4 interaction, stabilizing weak TCR-p:MHCII complexes and enabling reliable detection of low affinity TCR interactions that would otherwise be undetectable
3Adaptability or versatility
If wild type MHCII beta chains are used, then the molecules maintain natural peptide binding specificity, but they have insufficient affinity for CD4 co-receptors to activate low affinity TCRs
Solution Approach 1:
The patent applies local quality by making targeted amino acid substitutions specifically in the CD4-binding region of the MHCII beta chain while preserving the peptide-binding groove and overall molecular structure. This localized modification enhances CD4 affinity and T cell activation efficiency without compromising the molecule's ability to bind specific peptides with high specificity
Data Source
AI summary
The present disclosure provides variant major histocompatibility complex class II (MHCII) beta chains, as well as heterodimers and multimers including MHCII alpha chains and the variant MHCII beta chains. Also provided by the present disclosure are nucleic acids, expression cassettes, and expression vectors encoding the MHCII beta chains. The heterodimers and multimers of the present disclosure have a higher affinity for CD4 co-receptors than comparable reagents including wild type MHCII beta chains, and therefore are advantageous for use in methods of phenotyping or activating CD4+ T cells.